全文获取类型
收费全文 | 13846篇 |
免费 | 1173篇 |
国内免费 | 414篇 |
专业分类
耳鼻咽喉 | 212篇 |
儿科学 | 595篇 |
妇产科学 | 296篇 |
基础医学 | 1676篇 |
口腔科学 | 277篇 |
临床医学 | 1074篇 |
内科学 | 1348篇 |
皮肤病学 | 239篇 |
神经病学 | 776篇 |
特种医学 | 937篇 |
外国民族医学 | 5篇 |
外科学 | 2068篇 |
综合类 | 1453篇 |
现状与发展 | 4篇 |
预防医学 | 295篇 |
眼科学 | 155篇 |
药学 | 607篇 |
11篇 | |
中国医学 | 135篇 |
肿瘤学 | 3270篇 |
出版年
2024年 | 8篇 |
2023年 | 240篇 |
2022年 | 344篇 |
2021年 | 550篇 |
2020年 | 562篇 |
2019年 | 501篇 |
2018年 | 448篇 |
2017年 | 447篇 |
2016年 | 548篇 |
2015年 | 539篇 |
2014年 | 900篇 |
2013年 | 980篇 |
2012年 | 754篇 |
2011年 | 724篇 |
2010年 | 611篇 |
2009年 | 578篇 |
2008年 | 662篇 |
2007年 | 641篇 |
2006年 | 565篇 |
2005年 | 506篇 |
2004年 | 437篇 |
2003年 | 328篇 |
2002年 | 290篇 |
2001年 | 270篇 |
2000年 | 224篇 |
1999年 | 189篇 |
1998年 | 211篇 |
1997年 | 169篇 |
1996年 | 168篇 |
1995年 | 191篇 |
1994年 | 206篇 |
1993年 | 141篇 |
1992年 | 142篇 |
1991年 | 151篇 |
1990年 | 130篇 |
1989年 | 102篇 |
1988年 | 99篇 |
1987年 | 87篇 |
1986年 | 93篇 |
1985年 | 105篇 |
1984年 | 99篇 |
1983年 | 60篇 |
1982年 | 76篇 |
1981年 | 89篇 |
1980年 | 74篇 |
1979年 | 60篇 |
1978年 | 42篇 |
1977年 | 41篇 |
1976年 | 30篇 |
1975年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Desmoid-type fibromatosis (DF) is a distinctly rare condition, mostly of younger adults, characterized by the development of locally aggressive tumors of mesenchymal origin. Desmoid tumors (DT) arise either sporadically or in association with FAP (familial adenomatous polyposis), although certain risk factors have also been identified, including pregnancy and antecedent surgical trauma. They can emerge from any connective tissue including muscle, fascia and aponeurosis and are therefore classified, according to location, as intra-abdominal, of the abdominal wall and extra-abdominal. Despite the lack of metastasizing potential, the course can be unpredictable. Various mutations of APC and β-catenin genes, among others, play a catalytic role in the pathogenesis of this neoplastic entity. Surgery has lost its traditional role as first line treatment of the disease and several other treatment methods are being considered. Cytotoxic chemotherapy, non-cytotoxic systemic therapy and targeted therapy have been revealed as part of different treatment regimens. Recent progress regarding DT biology and molecular pathways has led to the development of promising novel biological agents. In any case, a multidisciplinary approach is required and is gradually employed, espe-cially in intra-abdominal DTs. In this review, we aim to present current knowledge on DF and summarize current treatment regimens as well as their effectiveness, with emphasis on the intraperitoneal type of DT. 相似文献
2.
3.
Qing-Yang Que Lin-Cheng Zhang Jia-Qi Bao Sun-Bin Ling Xiao Xu 《World journal of gastrointestinal surgery》2022,14(5):397-408
Over the last 40 years, the incidence and prevalence of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) have continued to increase. Compared to other epithelial neoplasms in the same organ, GEP-NENs exhibit indolent biological behavior, resulting in more chances to undergo surgery. However, the role of surgery in high-grade or advanced GEP-NENs is still controversial. Surgery is associated with survival improvement of well-differentiated high-grade GEP-NENs, whereas poorly differentiated GEP-NENs that may benefit from resection require careful selection based on Ki67 and other tissue bio markers. Additionally, surgery also plays an important role in locally advanced and metastatic disease. For locally advanced GEP-NENs, isolated major vascular involvement is no longer an absolute contraindication. In the setting of metastatic GEP-NENs, radical intended surgery is recommended for patients with low-grade and resectable metastases. For unresectable metastatic disease, a variety of surgical approaches, including cytoreduction of liver metastasis, liver transplantation, and surgery after neoadjuvant treatment, show survival benefits. Primary tumor resection in GEP-NENs with unresectable metastatic disease is associated with symptom control, prolonged survival, and improved sensitivity toward systemic therapies. Although there is no established neoadjuvant or adjuvant strategy, increasing attention has been given to this emerging research area. Some studies have reported that neoadjuvant therapy effectively reduces tumor burden, improves the effectiveness of subsequent surgery, and decreases surgical complications. 相似文献
4.
5.
6.
目的:探讨消化道肿瘤中同源重组修复相关基因(homologous recombination repair related gene,HRR)突变的发生情况及临床意义。方法:共92例消化道肿瘤患者,79例患者进行了血液标本HRR检测,53例患者进行了组织标本HRR检测,40例患者同时行血液和组织的HRR基因检测,收集患者基因检测结果及临床相关资料。结果:在79例患者血液标本检测中发现10例(12.6%)有临床意义HRR突变,在53例患者组织标本检测中发现9例(17.0%)有临床意义HRR突变。40例同时行血液和组织的HRR基因检测患者中常见的有临床意义HRR突变为CDK12突变4例(10.0%)、ATM突变3例(7.5%)、BRCA1突变2例(5.0%)。13例有临床意义HRR突变患者中常见共存突变为TP53突变10例(76.9%)、APC突变5例(38.5%)、PIK3CA突变4例(30.8%)。40例患者中13例患者血液和/或组织中有临床意义HRR突变,27例患者血液和组织中均无任何临床意义HRR突变且两组相比,有临床意义HRR突变组肿瘤突变负荷(tumor mutational burden,TMB)为6.17(2.24~11.52),而未携带HRR突变组TMB为0.4(0~3.75),差异有统计学意义(P<0.05)。40例患者组织检测中7例HRR有临床意义的突变,33例无HRR突变,血液检测中10例HRR有临床意义的突变,30例无HRR突变,一致性检验的Kappa值为0.333(P=0.031)。结论:携带有临床意义HRR突变的消化道肿瘤患者TMB更高,血液和组织检测HRR突变有较好的一致性。 相似文献
7.
8.
9.
《Diagnostic Histopathology》2021,27(12):506-518
Recent discovery of new disease-defining molecular alterations and development of novel targeted therapies has dramatically changed the classification and management of uterine mesenchymal neoplasms. This review discusses diagnostic updates in endometrial stromal sarcoma, PEComa, uterine tumor resembling ovarian sex cord tumor (UTROSCT), inflammatory myofibroblastic tumor, NTRK fusion uterine sarcoma, COL1A1-PDGFB fusion sarcoma, and SMARC-deficient uterine sarcoma. Key clinical, morphologic, immunophenotypic, and molecular features are reviewed, with emphasis on common differential diagnoses and pitfalls, and their impact on prognosis or management. Where applicable, the role of novel targeted therapies is discussed. A stepwise approach to uterine mesenchymal neoplasms can achieve a proper diagnosis and guide appropriate clinical management in most cases. Nonetheless, given the rarity of these tumors, their overlapping pathologic features, and rapid evolution in their classification and management, we advocate a low threshold for diagnostic consultation. 相似文献
10.
聚腺苷二磷酸核糖聚合酶(PARP)是一类在真核细胞中高表达的核酶,在DNA损伤修复中起关键作用。近年来,PARP抑制剂在肿瘤治疗中显示出巨大的潜力,几种小分子PARP抑制剂已被美国食品药品管理局(FDA)批准用于多种肿瘤的维持治疗。PARP抑制剂主要通过抑制PARP酶促作用和PARP捕获作用,导致DNA单链断裂的持续存在,在DNA复制的过程中,转变为双链断裂。研究证明,PARP抑制剂不仅具有显著的抗肿瘤效应,而且与放射治疗联合具有一定的协同作用。本文将阐述PARP抑制剂联合放疗的潜在理论基础,总结近年来PARP抑制剂在肿瘤放射治疗中的临床前和临床研究进展,梳理该领域目前亟待解决的问题,并对其在抗肿瘤治疗中的应用前景进行展望。 相似文献